2017
Co‐inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma
Lucca LE, Hafler DA. Co‐inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunological Reviews 2017, 276: 9-25. PMID: 28258696, PMCID: PMC5338636, DOI: 10.1111/imr.12529.Peer-Reviewed Original ResearchConceptsCheckpoint immunotherapyTumor rejectionCommon adult brain tumorsImmune-related side effectsCheckpoint receptor blockadeCo-inhibitory receptorsIntroduction of immunotherapyT cell exhaustionImmune regulatory pathwaysCo-inhibitory pathwaysAdult brain tumorsPrevention of autoimmunityCentral nervous systemAnti-tumor activityDifferent tumor typesCheckpoint inhibitorsReceptor blockadeAdvanced cancerTherapeutic successBrain tumorsSide effectsImmunotherapyNervous systemTherapeutic efficacyTumor types
2014
Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses
Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, Xia J, Tan TG, Sefik E, Yajnik V, Sharpe AH, Quintana FJ, Mathis D, Benoist C, Hafler DA, Kuchroo VK. Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses. Immunity 2014, 40: 569-581. PMID: 24745333, PMCID: PMC4070748, DOI: 10.1016/j.immuni.2014.02.012.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell ProliferationCells, CulturedCytokinesEosinophilsFibrinogenForkhead Transcription FactorsGene Expression ProfilingGene Expression RegulationImmunosuppression TherapyLymphocyte ActivationMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicReceptors, ImmunologicRespiratory HypersensitivityTh1-Th2 BalanceT-Lymphocyte SubsetsT-Lymphocytes, RegulatoryConceptsTreg cell subsetsTh2 cell responsesTreg cellsCell subsetsCell responsesProinflammatory T helper 1T effector cell proliferationTreg cell-mediated suppressionFibrinogen-like protein 2Allergic airway inflammationT regulatory (Treg) cellsTh2 cytokine productionSuppression of Th1T helper 1Effector cell proliferationTreg signature genesProinflammatory Th1TIGIT expressionAirway inflammationTh17 cellsRegulatory cellsHelper 1Cytokine productionT cellsImmune response
2006
Human regulatory T cells and their role in autoimmune disease
Baecher‐Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunological Reviews 2006, 212: 203-216. PMID: 16903916, DOI: 10.1111/j.0105-2896.2006.00417.x.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAutoimmune DiseasesCD4 AntigensCell SeparationHumansImmunosuppression TherapyReceptors, Interleukin-2Self ToleranceT-Lymphocytes, RegulatoryConceptsRegulatory T cellsAutoimmune diseasesSelf-reactive cellsT cellsHealthy individualsHuman natural regulatory T cellsSelf-reactive T cellsNatural regulatory T cellsHuman regulatory T cellsPathologic T cellsReduced inhibitory functionSpecific autoimmune diseasesT cell populationsMature T cellsT cell maturationNon-responsive stateRegulatory cellsNatural CD4Peripheral circulationImmune systemPatientsDiseaseInhibitory functionNumber of mechanismsCells
2005
Multiple sclerosis
Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher‐Allan C. Multiple sclerosis. Immunological Reviews 2005, 204: 208-231. PMID: 15790361, DOI: 10.1111/j.0105-2896.2005.00240.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnimalsAutoantibodiesCentral Nervous SystemGenetic VariationHumansImmunosuppression TherapyMultiple SclerosisT-LymphocytesConceptsMultiple sclerosisT cellsB cellsImmunopathology of MSCentral nervous system white matterNervous system white matterRegulatory T cellsHallmark of inflammationImmunosuppressive therapyAutoimmune processImmunomodulatory therapeuticsAnimal modelsMS researchWhite matterDisease pathologyClonal expansionDiseaseMajor histocompatibility complex (MHC) genesMolecular pathologyRNA expressionSclerosisInflammationTherapyPathologyComplex genetic diseases
1995
Antigen-Specific Immunosuppression: Oral Tolerance for the Treatment of Autoimmune Disease
Hafler DA, Weiner HL. Antigen-Specific Immunosuppression: Oral Tolerance for the Treatment of Autoimmune Disease. Chemical Immunology And Allergy 1995, 60: 126-149. PMID: 7857525, DOI: 10.1159/000423974.Peer-Reviewed Original Research
1988
Anti‐CD4 and Anti‐CD2 Monoclonal Antibody Infusions in Subjects with Multiple Sclerosis Immunosuppressive Effects and Human Antimouse Responses
HAFLER D, WEINER H. Anti‐CD4 and Anti‐CD2 Monoclonal Antibody Infusions in Subjects with Multiple Sclerosis Immunosuppressive Effects and Human Antimouse Responses. Annals Of The New York Academy Of Sciences 1988, 540: 557-559. PMID: 2905125, DOI: 10.1111/j.1749-6632.1988.tb27171.x.Peer-Reviewed Original ResearchImmunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology 1988, 38: 9-14. PMID: 2838768.Peer-Reviewed Original ResearchMeSH KeywordsAdrenocorticotropic HormoneCyclophosphamideFollow-Up StudiesHumansImmunosuppression TherapyLeukopeniaMultiple SclerosisConceptsProgressive multiple sclerosisChronic progressive multiple sclerosisMultiple sclerosisShorter disease durationMajority of patientsDosage of medicationCurrent treatment programsInduction regimenComplication rateDisease durationFrequent complicationLate complicationsYounger patientsPermanent remissionTreatment regimenInitial treatmentBooster injectionMaintenance treatmentMinor infectionsPatientsRemissionTreatment programRegimenComplicationsSingle treatmentImmunosuppression with monoclonal antibodies in multiple sclerosis.
Hafler DA, Weiner HL. Immunosuppression with monoclonal antibodies in multiple sclerosis. Neurology 1988, 38: 42-7. PMID: 3260356.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibody FormationHumansImmunosuppression TherapyMultiple SclerosisPhenotypeT-LymphocytesConceptsHuman anti-mouse antibodiesChronic progressive multiple sclerosisAnti-T cell mAbsAnti-mouse antibodiesProgressive multiple sclerosisMAb infusionsMultiple sclerosisChronic diseasesT11 mAbPhase I clinical studyAnti-idiotypic activityMonoclonal antibody infusionMore chronic diseasesT cell subpopulationsAnti-mouse responseHuman immune responseAnti-idiotypic antibodiesHuman anti-mouse responseT cell activationAcute immunosuppressionT cell surfaceAntibody infusionImmunologic responseRepeated administrationIgG isotype